Saratov JOURNAL of Medical and Scientific Research

Combined approach to the surgical treatment of patients with prolifera-tive stage of diabetic retinopathy

Year: 2017, volume 13 Issue: №2 Pages: 338-345
Heading: Ophtalmology Article type: Original article
Authors: Bikbov M.M., Fayzrakhmanov R.R., Kalanov M.R.
Organization: State Budgetary Institution "Ufa eye research institute of the Academy of Sciences of the Republic of Bashkortostan"
Summary:

Purpose: to evaluate the effectiveness of combined surgical treatment in patients with proliferative stage of diabetic retinopathy. Material and Methods. 52 patients with advanced stage of proliferative diabetic retinopathy who were divided into 2 groups were examined. Group 1 consisted of 30 patients with a preliminary intravitreal injection of ranibi-zumab, followed by vitrectomy In group 2, 22 patients underwent vitrectomy without anti-VEGF therapy. Visual acuity in the 1st group before treatment was 0.04±0.02, in the second 0.05±0.03. The thickness of the retina in the foveolar zone of the 1st group was 358±34 urn, in the second 378±44 urn. Height of the complex "PHM with fibro-glial proliferation — retina" 670±38 and 710±30, respectively. Results. The visual acuity after treatment increased 4.2 times (group 1), in comparison with the results of the second group by 2.5 times. In patients of the 1st group intraoperative hemor-rhagic manifestations were observed in 36.6% of cases, in the 2nd group in all patients. An increase in the height of the complex "PHM with fibro-glial proliferation — retina" was noted in 83.3% in patients of the 1st group one month after the injection. The height of the complex increased on average to 153±25 urn, which in 76.6% increased the traction effect on the retina. The neovascularization regression occurred 4-8 days after ranibizumab injection in group 1 patients. The retinal thickness of the central zone 10 months after vitrectomy decreased to 220±10 urn in the 1st group and to 273±14 urn in the 2nd group, respectively. Conclusion. The use of inhibitors of angiogenesis, in particular ranibizumab, as a preoperative preparation of patients with proliferative stage of diabetic retinopathy reduces the risk of intra- and postoperative hemorrhagic complications, which facilitates the implementation of vitrectomy, avoids additional vitreo-retinal interventions, in connection with which a positive functional result remains.

Bibliography:
1. Diabetes Atlas. 6th ed. IDF. URL: http://www.diabetesatlas.org/component/attachments/?task=do wnload&id=76(2013)
2. Diabetes Atlas. 4th ed. IDF. URL: http://www.diabetesatlas.org/component/attachments/?task=do wnload&id=75 (2009)
3. Khodjaev NS. International project "Barometer of diabetic retinopathy". New in Ophthalmology 2015; (4): 56-60
4. Shaw JE, Sicree RA, Zimmet PZ. Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Research and Clinical Practice 2010; 87 (1): 4-14
5. Bikbov MM, Fayzrakhmanov RR, Gil'manshin TR, Gilyazova II. The effect of an intravitreal implant with dexamethasone on the parameters of the foveolar zone in the occlusion of the central vein of the retina. Vestnik oftal'mologii 2016; (2): 21-25
6. Elia JD. Diabetic Retinopathy. Humana Press, a part of Springer Science + Business Media. LLC 2008: 500
7. Sdobnikova IV. The role of removal of the posterior membrane in the transvitreal surgery of proliferative diabetic retinopathy. PhD abstract. Moscow, 1996; 121 p.
8. WHO. Prevention of blindness from diabetes mellitus: Report of a WHO consultation in Geneva. Switzerland. WHO press 2005: 39
9. Bikbov MM, Fayzrakhmanov RR, Yarmukhametova AL, Kalanov MR. Modern approaches to the surgical treatment of proliferative diabetic retinopathy. Medical Almanac 2015; (1): 86-89
10. Michaelson 1С. The mode of development the vascular system of the retina with some observation on its significance for certain retinal disorders. Trans Ophthalmol Soc UK 1948; 68: 137-180
11. Bikbov MM, Fayzrakhmanov RR, Yarmukhametova AL. Morphometric evaluation of the macular zone with spongy diabetic macular edema on the background of antivasoproliferative therapy. Vestnik Oftal'mologii 2014; 130 (1): 37-41
12. Senger DR, Galli SJ, Dvorak AM, et al. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 1983; 219: 983-985
13. Miller JW, Adamis AP, Shima DT, et al. Vascular endothelial growth factor/vascular permeability factor is temporally and spatially correlated with ocular angiogenesis in a primate model. Am J Ophthalmol 1994; 145: 574-584
14. Bikbov MM, Fayzrakhmanov RR. Features of antivasoproliferative therapy in patients with active fibrovascular membrane in age-related macular degeneration. Medical Almanac 2015; 36 (1): 93-95
15. Ning Ch, Ian YW, Tien YW. Ocular Anti-VEGF Therapy for Diabetic Retinopathy: Overview of Clinical Efficacy and Evolving Applications. Diabetes Care 2014; 37 (4): 900-905
16. Do DV, Nguyen QD, Vitti R, et al. Intravitreal Aflibercept Injection in Diabetic Macular Edema Patients with and without Prior Anti-Vascular Endothelial Growth Factor Treatment: Outcomes from the Phase 3 Program. Ophthalmol 2016; 123 (4): 850-706
17. Fayzrakhmanov RR, Yarmukhametova AL, Kalanov MR. Combined surgical treatment of patients with proliferative stage of diabetic retinopathy. Tochka zreniya. Vostok — Zapad 2016; (1): 116-120
18. Mitchell Р, Bandello F, Schmidt-Erfurth U, et al. The RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema. Ophthalmol 2011; 118: 615-625
19. Nguyen QD, Shah SM, Heier JS, et al. Primary end point (six months) results of the Ranibizumab for Edema of the macula in diabetes (READ-2) study. Ophthalmol 2009; 116: 2175-2181
20. Katsnel'son LA. Clinical forms of diabetic retinopathy Vestnik oftal'mologii 1979; 6: 43-47
21. L'Esperance FA. Jr, James WA. Jr, Friedman EA, et al. Long-term retention of vision following vitrectomy in diabetic patients. Diabetes Care 1981; 4 (6): 631-633
22. Waisbourd M, Goldstein M, Loewenstein A. Treatment of diabetic retinopathy with anti-VEGF drugs. Acta Ophthalmol 2011; 89(3): 203-207
23. Neroev VV, Sarygina Ol, lljuhin PA. The role of ranibizumab in the prevention of complications in the surgery of proliferative diabetic retinopathy. Rossijskij oftal'mologicheskij zhurnal 2011; 4 (4): 54-58.

AttachmentSize
2017_02-1_338-345.pdf2.47 MB

No votes yet